OTTAWA, May 20
/PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS;
http://www.htdsmedical.com/) Collagenna Skin Care Products has
entered into a distribution agreement with the Texas Beauty
Institute of the Dallas/Fort Worth
Area www.texasbeautyinstitute.com
The Texas Beauty Institute (TBI) is a leader in the field of
non-invasive cosmetic recovery solutions and is constantly doing
research to develop natural anti-aging techniques. TBI has
researched and developed protocols for advanced micro current
therapies which maximize the penetration of elastin and collagen
into the skin.
Collagenna Skin Care Products CEO Michael Arnkvarn states, "When we first started
talking with TBI's CEO, Mr Nelson
Thibodeaux, it became very apparent that our companies were
a good fit. Our collagen and peptide technologies used in
combination with TBI's infusion therapies will give maximum
results. As well TBI works with Chiropractors all over the
USA and this will offer a
tremendous opportunity to market our Melem Secret line of
supplements as part of their message of natural health. We have
started putting in place a marketing program in the Dallas/Fort Worth area to help TBI introduce
the Collagenna product line."
The Texas Beauty Institute will distribute the Collagenna
product line to other clinics as well as sell the product to their
retail customers. They have recently updated their website and the
Collagenna Product line can be purchased by retail customers on
their ecommerce site as well as by their wholesale clients in the
site's backroom.
Collagenna Skin care Products/Melem Secret is continuing its
global expansion in order to meet its financial targets for 2010.
TBI is another important partner in this equation
The company reminds our shareholders and followers that the
company does not subscribe to the PinkSheets.Com Filing Service.
Its IR company web site section "CLIENT SUPPORT" TAB
www.minamargroup.net or this direct link
http://minamarmarketinggroup.helpserve.com/ should be reviewed by
its followers for further updates on this and other business
matters. Non-newsworthy events are not press released however
posted on this separate support sites to keep our followers advised
of day-to-day events, and the company corporate web site. For any
matters relating to retail investor queries or to send us the
company directly a message please click on the "INVESTOR SUPPORT"
TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases,
industry updates, and non-weekly activity at the company that may
or may not be news released, please subscribe or opt in mailer at
www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future
expectations, plans, prospects or performance of Hard to Treat
Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provision's under the Private
Securities Litigation Reform Act of 1995. The words or phrases "can
be," "expects," "may affect," "believed," "estimate," "project,"
and similar words and phrases are intended to identify such
forward-looking statements. HTDS Corporation cautions you that any
forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None
of the information in this filing constitutes or is intended as an
offer to sell securities or investment advice of any kind. Hard to
Treat Diseases, Inc.'s actual results may differ materially from
those anticipated in such forward-looking statements as a result of
various important factors, some of which are beyond Hard to Treat
Diseases, Inc.'s control. In addition to those discussed in Hard to
Treat Diseases, Inc.'s press releases, public filings, and
statements by Hard to Treat Diseases, Inc.'s management, including,
but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future
operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market
opportunities and, in identifying contracts which match Hard to
Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such statements were made. Hard to Treat Diseases, Inc. does not
undertake any obligation to publicly update any forward-looking
statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of
unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com; For any corporate
matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases